India, Sept. 17 -- Dr. Reddy's Laboratories has announced a royalty-free non-exclusive voluntary licensing agreement with Gilead Sciences for investigational once-yearly lenacapavir for HIV prevention as pre-exposure prophylaxis (PrEP).

The agreement builds on Dr. Reddy's existing voluntary licensing arrangement with Gilead, signed in October 2024, for twice-yearly lenacapavir for HIV prevention and treatment and reflects the continued confidence between the two companies as they work towards broadening future access to long-acting HIV prevention options in licensed markets. The agreement aims to facilitate manufacturing readiness, technology transfer and future supply planning for investigational once-yearly lenacapavir while clinical d...